Enhancing biological knowledge through proteomics

Measures the concentration of thousands of human proteins using minimal sample quantities.

More Data. Less effort.  

Thanks to its proprietary Proximity Extension Assay (PEA) technology, Olink® Explore enables accurate and simultaneous quantification of hundreds to thousands of protein biomarkers secreted in human body fluids. The Olink platform offers the accuracy and sensitivity of manual techniques with minimal sample requirements.


The incorporation of NGS allows greater scalability of samples and biomarkers analyzed simultaneously without affecting data quality and reducing costs.



Data analysis

Explore 384-plex panels

Olink Explore technology consists of eight Explore 384-plex panels focused on diseases and biological processes. This flexible and scalable offer uses approximately 1 µL of blood sample per 384-plex panel.
You can test all panels simultaneously (Explore 3072) or focus on one or more of the Explore 384-plex panels.

Olink® Explore 384 Cardiometabolic I and II

Olink® Explore 384 Inflammation I and II

Olink® Explore 384 Neurology I and II

Olink® Explore 384 Oncology I and II

Olink Explore panels contain biomarkers to answer key research questions, covering as many metabolic pathways and functions as possible.



Endless possibilities on a single platform

Olink Explore is a high-value platform for studies involved in drug development, clinical research or basic research aiming to perform large-scale discovery proteomics studies.

What makes Olink® Explore different?

The study of the secretome has been limited by the lack of tools to accurately and precisely analyze its complexity. Olink Explore provides an answer to all these limitations:

High sensibility

Outstanding specificity

>3.000 biomarkers

Minimal sample requirements (<1 μl para 384-plex, <6 μl para 3072-plex)

Broad dynamic range (femtograms to milligrams)

Innovation for protein biomarker discovery and protein analysis

~3000 validated protein assays

Covers all major biological pathways

High sample throughput

Suitable for large-scale proteomics studies

Minimal sample requirements

Uses just 6µL for the complete library, saving precious biological samples

– Outstanding specificity

Provides results you can trust thanks to our proprietary PEA technology

– High sensitivity and broad dynamic range

Enables the analysis of both low and high-abundance proteins (fg/mL – mg/mL)

Innovación para el descubrimiento de biomarcadores proteicos y el análisis de proteínas

Alto rendimiento de muestras

Adecuado para estudios proteómicos a gran escala

~3000 ensayos de proteinas validados

Cubre las principales vías biológicas

Consumo mínimo de muestras

Utiliza sólo 6µL para la biblioteca completa, conservando valiosas muestras biológicas

Expecifidad excepcional

Proporciona resultados fiables gracias a nuestra tecnología PEA

Alta sensibilidad y amplio rango dinámico

Permite el análisis tanto de proteínas de baja como de alta abundancia (fg/mL – mg/mL)

Unprecedented power

Olink Explore has emerged as an essential technology in personalized medicine for the identification and monitoring of biomarkers for early diagnosis, prognosis, improved patient stratification, and follow-up of treatment response (>1,400 publications).

Supporting the complete drug development process


Discovery of a therapeutic target

Preclinical research

In vivo/in vitro testing

Clinical development

Phase 1

Dosage and safety

Phase 2

Efficacy/side effects

Phase 3

Effect/adverse event

Phase 4

Post-market surveillance

Olink® Explore panels

We capture genuine biological information with proven specificity. At any scale.

Cardiometabolic II









Inflammation II






Oncology II






Neurology II



Explore 3072



Our workflow

First session

Analysis service contract and dispatch of the sample form

Samples delivery

Sample processing

Results analysis

Report submission


Plasma proteomic signature of fatty liver disease: the Rotterdam Study.”

(2023) Hepatology, DOI: 10.1097/

Abozaid YJ, Ayada I, van Kleef LA, et al.

Article link

“Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro-Inflammatory Molecular Profile.”

(2023) Ocular Immunology and Inflammation, DOI: 10.1080/09273948.2023.2182325

Achten R, van Luijk C, Thijs J, et al.

Article link

“Genetic variants associated with syncope implicate neural and autonomic processes.”

(2023) Journal of Allergy and Clinical Immunology: Global, DOI: 10.1016/j.jacig.2023.100093

Aegisdottir HM, Thorolfsdottir RB, Sveinbjornsson G, et al.

Article link

“Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation.”

(2023) ESC Heart Failure, DOI: 10.1002/ehf2.14399

Ahmed A, Kania K, Abdul Rahim H, et al.

Article link

“Granzymes, IL-16, and poly(ADP-ribose) polymerase 1 increase during wildfire smoke exposure.”

(2023) Journal of Allergy and Clinical Immunology: Global, DOI: 10.1016/j.jacig.2023.100093

Aguilera J, Kaushik A, Cauwenberghs N, et al.

Article link

“Disease duration and chronic complications associate with immune activation in individuals with longstanding type 1 diabetes.”

(2023) Journal of Clinical Endocrinology and Metabolism, DOI: 10.1210/clinem/dgad087l

Ajie M, van Heck JIP, Janssen AWM, et al.

Article link

“Novel Biomarkers of Necrotizing Enterocolitis in Neonates Undergoing Congenital Heart Disease Surgery: A Pilot Cohort Study”

(2023) Journal of the American Heart Association, DOI: 10.1161/JAHA.123.030712

Ali EA, Syed A, Khailova L, et al.

Article link

“Unique immune and inflammatory cytokine profiles may define long COVID syndrome. “

(2023) Clinical and Experimental Medicine, DOI: 10.1007/s10238-023-01065-6

Allan-Blitz LT, Akbari O, Kojima N, et al.

Article link

Do you have any questions?

Request a budget here!